Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sonnet Biotherapeutics Holdings Inc (SONN)

Sonnet Biotherapeutics Holdings Inc (SONN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,218
  • Shares Outstanding, K 3,069
  • Annual Sales, $ 150 K
  • Annual Income, $ -18,830 K
  • 60-Month Beta 0.64
  • Price/Sales 34.64
  • Price/Cash Flow N/A
  • Price/Book 2.16
Trade SONN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -7.47
  • Growth Rate Est. (year over year) +13,473.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6500 +7.27%
on 04/16/24
2.3273 -23.95%
on 03/19/24
-0.4900 (-21.68%)
since 03/18/24
3-Month
1.3000 +36.15%
on 01/22/24
2.3399 -24.36%
on 03/18/24
+0.4350 (+32.58%)
since 01/18/24
52-Week
1.0800 +63.89%
on 10/26/23
26.4000 -93.30%
on 06/16/23
-5.5648 (-75.87%)
since 04/18/23

Most Recent Stories

More News
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

PRINCETON, NJ / ACCESSWIRE / October 31, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, provided a fiscal year...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

PRINCETON, NJ / ACCESSWIRE / October 25, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targeted...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

PRINCETON, NJ / ACCESSWIRE / October 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

PRINCETON, NJ / ACCESSWIRE / September 20, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy

PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase 1b/2a...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second Phase...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition

PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

- IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and SON-1410...

SONN : 1.7700 (+4.12%)
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors

PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has...

SONN : 1.7700 (+4.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.

See More

Key Turning Points

3rd Resistance Point 1.8717
2nd Resistance Point 1.8233
1st Resistance Point 1.7967
Last Price 1.7700
1st Support Level 1.7217
2nd Support Level 1.6733
3rd Support Level 1.6467

See More

52-Week High 26.4000
Fibonacci 61.8% 16.7278
Fibonacci 50% 13.7400
Fibonacci 38.2% 10.7522
Last Price 1.7700
52-Week Low 1.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar